Novartis Seeks To Be Generics “Powerhouse” With Eon, Hexal Acquisitions
Executive Summary
Novartis expects the addition of Eon Labs and Hexal AG to its Sandoz division to create a generic drug "powerhouse" that will play a major role in the emerging "authorized" generics and follow-on biologics markets
You may also be interested in...
Novartis Catches Flu Fever: Second Bid Nets Chiron
Novartis' first priority upon the completion of its acquisition of Chiron will be to resolve the flu vaccine maker's outstanding manufacturing issues, Novartis Head of Pharma Development Jörg Reinhardt said during an analyst call announcing the deal Oct. 31
Novartis Catches Flu Fever: Second Bid Nets Chiron
Novartis' first priority upon the completion of its acquisition of Chiron will be to resolve the flu vaccine maker's outstanding manufacturing issues, Novartis Head of Pharma Development Jörg Reinhardt said during an analyst call announcing the deal Oct. 31
Sandoz Acquisitions Will Contribute $1.3 Bil. To 2005 Sales, Novartis Says
The integration of the generic drug makers Hexal and Eon Labs into Novartis' Sandoz unit is proceeding ahead of schedule, Novartis reported